Key facts
- Notable investors include SOSV, IndieBio.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Finish Line Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Finish Line Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Finish Line Bio
Provider of strain engineering and genetic optimization services based in Berkeley, California. The company offers a database that identifies genetic modifications for engineered strains, host strain health analysis, and tailored consulting for fermentation-based production.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2024
- Website
- finishlinebio.com/
- Ownership
- Privately Held (backing)
Finish Line Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Finish Line Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Finish Line Bio in its N-PORT filings yet. We sweep new filings monthly.